Pharmaceuticals
PharmaZell and Novasep enter into exclusive negotiations in new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
RAUBLING, Germany and LYON, France, Sept. 17, 2021 /PRNewswire/ -- PharmaZell, the German producer of highly resilient and specialty APIs, andFrance-based Novasep, a leading CDMO focused on complex small molecules and ADCs have entered into exclusive negotiations to create a leading European plat...
2021-09-17 03:59
3480
Nippon Express (Taiwan) Establishes New Logistics Base in Taoyuan City
TOKYO, Sept. 16, 2021 /PRNewswire/ -- Nippon Express (Taiwan) Co., Ltd. (hereinafter "NE Taiwan"), a local subsidiary of Nippon Express Co., Ltd., established a new logistics base (NEXT3 Warehouse) in Taoyuan City in northern Taiwan in May, and obtained business licenses for cosmetics, pharmaceuti...
2021-09-16 15:00
2576
SuperTrans Medical supported by U.S. National Institutes of Health (NIH) in developing its lead antibiotic against urgent threat drug resistant bacteria
SYDNEY, Sept. 16, 2021 /PRNewswire/ -- SuperTrans Medical ("STM"), a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant bacterial infections, has announced that the U.S. National Institutes of Health (NIH) will be supporting additional dev...
2021-09-16 08:45
3886
Charles Bodner Joins CSafe Global as Chief Financial Officer
CSafe Global has hired Charles Bodner as CFO following Patrick Schafer's promotion to CEO in 2020. DAYTON, Ohio, Sept. 16, 2021 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today that Charles ('Chuck') Bodner h...
2021-09-16 06:25
5903
Prenetics, a Global Leader in Genomic and Diagnostic Testing, to Become Publicly Traded on the Nasdaq via Merger with Adrian Cheng's Artisan Acquisition Corp.
* Prenetics' mission is to disrupt and decentralise the healthcare industry with a global opportunity of overUS$1.3 trillion. * Prenetics' multi-product healthcare ecosystem strategy is driven by prevention focused genomic testing, rapid diagnostics for COVID-19 and infectious diseases, and c...
2021-09-16 06:00
8819
2021 Centre for Medicines Research (CMR) Pharmaceutical R&D Factbook from Clarivate Finds Drug Approvals at a 10-year High Despite the Challenges of COVID-19
LONDON, Sept. 15, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of the2021 Centre for Medicines Research (CMR) International Pharmaceutical R&D Factbook. The 2021 CMR ...
2021-09-15 16:00
1654
Sputnik V Demonstrates 97.2% Efficacy And High Safety Profile Against COVID During The Vaccination Campaign In Belarus
MOSCOW, Sept. 15, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces the real world data of the Ministry of Health of theRepublic of Belarus on the Russian Sputnik V coronavirus vaccine confirming its high efficacy during the vaccination campai...
2021-09-15 16:00
1960
CStone received China NMPA IND approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody, marking further expansion of its Pipeline 2.0
SUZHOU, China, Sept. 15, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the investigational ne...
2021-09-15 08:30
3920
BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs
VANCOUVER, BC, Sept. 14, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320, the company's COVID-19 vaccine candida...
2021-09-14 15:00
6575
Jemincare group has completed the Phase I clinical trial of its anti-SARS-CoV-2 neutralizing antibody JMB2002
SHANGHAI, Sept. 14, 2021 /PRNewswire/ -- Recently, Jemincare group has declared that it has completed phase I clinical trial of self-developed novel coronavirus specific neutralizing antibody (Project code: JMB2002). The clinical trial of JMB2002 was stated in January 2021. A single-center, rand...
2021-09-14 11:43
4860
Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
FREIBURG, Germany, Sept. 14, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more state-of-the-a...
2021-09-14 10:30
2312
CStone presents updated data from registrational clinical study of sugemalimab in patients with stage IV NSCLC in an oral presentation at IASLC 2021 WCLC
* Data with the longer follow-up showed that sugemalimab plus chemotherapy continued to demonstrate improvement in progression-free survival (PFS), after the primary efficacy endpoint was met at an interim PFS analysis last year * The updated data showed that the risk of disease progression or...
2021-09-14 08:30
5326
Global Investors Invest in Etana
JAKARTA, Indonesia, Sept. 14, 2021 /PRNewswire/ -- PT Etana Biotechnologies Indonesia (Etana)has secured a new round of investment led by Legend Capital along with Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and a consortium led by UOB Venture Management (UOBVM). This round of funds will b...
2021-09-14 08:00
7709
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expanded RHB-107, a nov...
2021-09-13 19:00
7050
Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors
HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phas...
2021-09-13 17:00
2239
Everest Medicines Enters into Comprehensive Agreements with Providence Therapeutics to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Asia Emerging Markets
SHANGHAI, Sept. 13, 2021 /PRNewswire/ -- Everest Medicines Limited
2021-09-13 17:00
5745
Cytiva triples single-use consumables capacity in China
* Three new manufacturing lines were successfully launched in under ten months, with an additional eight new lines planned to launch in Q3 2022. * Sustain and secure the supply chain for customers in China and the broader region. * With the use of Fortem™ film, Cytiva helps customers speed...
2021-09-10 16:33
4173
Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine
CHENGDU, China, Sept. 9, 2021 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
(Clover)
2021-09-09 19:51
3277
Gan & Lee Pharmaceuticals to present data at the 57th Annual European Association for the Study of Diabetes Meeting
BEIJING and BRIDGEWATER, N. J., Sept. 9, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is excited to present positive data from five abstracts which will be featured as short oral discussions at the 57th Annual European Ass...
2021-09-09 15:00
3402
WCLC 2021 | Mini Oral - Ascentage Pharma Announces Latest Data of Its Investigational Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) Combined with Osimertinib in Patients with EGFR TKI-Resistant Non-Small Cell Lung Cancer
SUZHOU, China, and ROCKVILLE, MD., Sept 9, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today reported the Phase Ib results of the dual Bcl-2/Bcl-xL inhi...
2021-09-09 08:26
7190
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
YY Group Enters New Era as YYForce, Expanding AI, Automation and Human-Robot Workforce Strategy; Nasdaq Ticker Changes to "YFOR"
2026-09-01 04:10
8352
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
2026-09-01 11:00
8293
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
8156
